Erasca, INC Form 4 insider transactions

Chief Medical Officer of Erasca, Shannon Morris, reports the acquisition of stock options.

Ebun Garner, General Counsel & Corp. Sec. of Erasca, Inc., reports the acquisition of common stock through the company's employee stock purchase plan and the grant of stock options.

Jonathan E. Lim, Chairman & CEO of Erasca, Inc., reports the acquisition of 2,500,000 stock options on February 3, 2025.

Director Alexander W. Casdin of Erasca, Inc. acquired 28,877 stock options in lieu of cash compensation for his board service in 2025.

Director Jean I. Liu of Erasca, Inc. was granted stock options in lieu of cash compensation for her board service in 2025.

Valerie Denise Harding, a director at Erasca, Inc., acquired 29,402 stock options in lieu of cash compensation for her board service in 2025.

Erasca director James Arthur Bristol acquired 45,678 stock options in lieu of cash compensation for his board service in 2025.

Director Michael David Varney acquired 60,000 stock options in Erasca, Inc. on June 20, 2024.

Director Valerie Denise Harding reports acquisition of stock options in Erasca, Inc.

Jean I. Liu, a director of Erasca, Inc., acquired 60,000 stock options on June 20, 2024, exercisable starting June 20, 2025.

Ebun Garner, General Counsel & Corp. Sec. of Erasca, Inc., reports the acquisition of stock options.

Chief Medical Officer of Erasca, Inc., Shannon Morris, reports acquisition of stock options.

Jonathan E. Lim, Chairman & CEO of Erasca, Inc., reports the acquisition of stock options on June 20, 2024.

David M. Chacko, CFO and CBO of Erasca, Inc., reports the acquisition of stock options.

Director Julie Hambleton acquired 60,000 stock options in Erasca, Inc. on June 20, 2024, according to a Form 4 filing.

Director Alexander W. Casdin reports the acquisition of stock options in Erasca, Inc.

Director James Arthur Bristol of Erasca, Inc. acquired 60,000 stock options on June 20, 2024, exercisable starting June 20, 2025.

Director Pratik S. Multani of Erasca, Inc. acquired 60,000 stock options exercisable at $2.03, vesting on June 20, 2025.

Director Alexander W. Casdin reports purchasing 80,000 shares of Erasca, Inc. at $2.274 per share, increasing his total holdings.